Does the Clinical and Therapeutic Profile of Eprosartan Contribute to End Organ Protection?
Journal of Clinical and Basic Cardiology 2005; 8 (1-4): 7-9
Journal of Clinical and Basic Cardiology 2006; 9 (Sonderheft 1): 6-8
Keywords: Angiotensin-II-Rezeptorblockade, Eprosartan, Hypertonie, Kardiologie, MOSES-Studie, Schlaganfall, angiotensin receptor blockade, cardiology, Eprosartan, hypertension, MOSES trial, stroke
Systemic hypertension is a major risk factor for premature morbidity and mortality. The diseases caused by hypertension can be serious and deadly. Therefore, various guidelines consistently recommend lower target levels of blood pressure for intervention. One important mechanism sustaining hypertension and causing target organ damage is the renin-angiotensin system. Hence, interruption of this system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) offers a useful avenue to lower the cardiovascular risk. Of particular benefit are ARBs, which not only lower the blood pressure effectively, but also cause no side effects. Thus, ARBs provide a logical and physiological approach to treat hypertension. Among all the available ARBs, eprosartan possesses a unique mechanism of action in inhibiting both the reninangiotensin system and also the sympathetic nervous system; this dual mechanism of action offers distinct physiological and pharmacological benefits to the patients. Studies have shown that eprosartan is not only effective in controlling hypertension, but also provides remarkable target organ protection.